Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
|
31081934 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
High expression of lncRNA MALAT1 along with low expression of breast cancer susceptibility gene 1 (BRCA1) were identified in septic mice and human skeletal muscle cells of sepsis.
|
31830649 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Cysteine peptidase-like activity (CPA) in sera of patients with breast cancer at different stages of disease and the influence of genetic predisposition associated with BRCA-1 gene mutations were analysed.
|
31683457 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Approximately 5-10% of breast carcinomas have been related to hereditary conditions and are attributable to pathogenic variants in the BRCA1 and BRCA2 genes, which is referred to as hereditary breast and ovarian cancer (HBOC) syndrome.
|
31786208 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Poly (ADP-ribose) polymerase (PARP) inhibitors exploit this deficiency through synthetic lethality and have emerged as promising anticancer therapies, especially in breast cancer gene (BRCA1 or BRCA2) mutation carriers.
|
31650446 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients harboring germline Breast Cancer susceptibility genes 1 and 2 (BRCA1/2) mutations are predisposed to developing breast, pancreatic, and ovarian cancers.
|
31575654 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Data on tumor characteristics, disease stage, and therapeutic decisions were collected on BRCA1/2 mutation carriers treated for breast cancer at the Chaim Sheba Medical Center.
|
31760168 |
2020 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aims of this study were to evaluate the program and describe breast cancer diagnoses for BRCA1, BRCA2, and other germline mutation carriers as well as high-risk noncarriers attending the BOCRMC.
|
31657879 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The c.5266dupC mutation is one of the most frequently reported mutations in BRCA1 and was identified in five breast cancer patients in our study.
|
31706072 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In contrast, breastfeeding did not influence breast cancer occurrence in BRCA1 mutation carriers' group (p=0.2321).
|
31424662 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
For both BRCA1 and BRCA2 mutation carriers, none of the smoking-related variables was associated with BC risk, except smoking for more than five years before a first full-term pregnancy (FFTP) when compared to parous women who never smoked.
|
31792088 |
2020 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
|
31823331 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
More than 80% of women with a breast cancer associated with a breast cancer type 1 (BRCA1) mutation develop a TNBC. microRNAs (miRNAs) play critical roles in diverse biological processes and are aberrantly expressed in several human neoplasms including breast cancer, where they function as actors of tumor onset, behavior, and progression.
|
31736084 |
2020 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We propose that BRCA1 methylation in blood-derived DNA could be a novel biomarker of increased breast cancer susceptibility, in particular for triple-negative tumors.
|
31469414 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>In vivo</i> therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained <i>EF2K</i> gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer.
|
31432749 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of <i>BRCA1/2</i> small-range mutations and large genomic rearrangements was 55.4% (36/65) for families with breast and ovarian cancer, 27.4% (67/244) for families with two or more cases of breast cancer, 18.5% (5/27) for families with male breast cancer, and 12.3% (25/203) for families with a single case of early-onset breast cancer.
|
31528241 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A total of 325 Japanese women with breast cancer (BC) (with or without invasive cancer) were referred for genetic counseling and underwent genetic testing for mutations in the BRCA1 and BRCA2 genes in Showa University Hospital between December 2011 and August 2016.
|
30652428 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D.
|
30552672 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, we used protein interaction assays to determine the binary interactions between the tBRCT domain and mTORC2 subunits, evaluated the impact of mTOR inhibition on the transcriptional function of the tBRCT, evaluated the impact of mTOR signaling on BRCA1 recruitment to DNA damage-induced foci and determined the breast cancer cell line response to mTOR inhibition dependent upon <i>BRCA1</i> expression and mutation.
|
31771139 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 germline mutations is associated with greater acute hematological toxicity in breast cancer patients.
|
30635808 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
<i>Method:</i> The mRNA level expression of the related genes of breast cancer was detected by FQ-PCR technique and the ratio of BRCA-1, Myc, C-erbB2 and β2 micro-globulin was used to express levels of BRCA-1, Myc and C-erbB2; the related proteins of breast cancer were detected through ELISA.
|
30622425 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our study demonstrates that ER-positivity worsens BC prognosis in BRCA1/BRCA2 mutation carriers, while prognosis for carriers with ER-negative tumors (including early-onset) is significantly better and comparable with that in ER-positive, older BC non-carriers.
|
31141992 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to investigate the effect of the combined treatment with cisplatin and radiation therapy on the biological characteristics of the osteosarcoma cell line MG-63 and the breast cancer 1 (BRCA1)-associated signaling pathways.
|
31807162 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
It has also been reported that risk of breast cancer at an early age is increased with full-term pregnancies if a woman is a BRCA1 mutation carrier.
|
30963174 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA1/2 germline mutations are associated with a high risk of breast cancer, which may preclude mutation carriers from breast-conserving surgery (BCS).
|
30895535 |
2019 |